XWPharma

Clinical stage company developing innovative medicines that will significantly improve the quality of life of patients suffering from neurodegenerative disorders. Focuses on validated MOAs and pursues efficient development pathways that are designed to de-risk the programs while delivering new chemical entities (NCEs) that aims to achieve superior efficacy without the limitations associated with currently available treatments. Lead program XW10172, a GABAB agonist NCE, internally discovered, novel, patented conjugate of the GABAB agonist oxybate, is ready to enter Phase 3 trial in the US for the treatment of narcolepsy and Phase 2 trial for treating sleep disorders in Parkinson’s Disease. XW10508, a glutamatergic NMDA antagonist and AMPA activator NCE for treatment-resistant depression and chronic pain successfully completed Phase 1.